Current thinking on the mechanistic basis of Alzheimer's and implications for drug development
- 6 August 2015
- journal article
- review article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 98 (5) , 469-471
Abstract
Alzheimer disease (AD) is the most common cause of dementia and is characterized by the aggregation and accumulation of two proteins in the brain, amyloid‐β (Aβ) and tau. Aβ and tau begin to buildup 15‐20 years before the clinical onset of AD dementia. Increasing evidence suggests that preventing or decreasing the amount of aggregated forms of both Aβ and tau in the brain can serve as potential disease‐modifying treatments for AD.Keywords
Funding Information
- The JPB Foundation and Cure Alzheimer's Fund
- National Science Foundation Graduate Research Fellowship (DGE-1143954)
This publication has 5 references indexed in Scilit:
- Three dimensions of the amyloid hypothesis: time, space and 'wingmen'Nature Neuroscience, 2015
- TREM2 Lipid Sensing Sustains the Microglial Response in an Alzheimer’s Disease ModelCell, 2015
- Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Aβ amyloidosisJournal of Experimental Medicine, 2012
- Beneficial effect of human anti-amyloid-β active immunization on neurite morphology and tau pathologyBrain, 2010
- Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of PathogenesisScience, 2003